149 results on '"Carraway H"'
Search Results
2. Genomic determinants of chronic myelomonocytic leukemia
3. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms
4. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
5. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
6. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
7. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation
8. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
9. P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGRESS)
10. P587: COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND MULTIPLE MYELOMA
11. O01 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TRAJECTORIES OF MDS EVOLUTION IN THE CONTEXT OF APLASTIC ANEMIA
12. O03 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: IMMUNE ESCAPE VIA CLASS I AND II HLA SOMATIC MUTATIONS IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA RELAPSING AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
13. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation
14. Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations
15. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α
16. p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage
17. Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter
18. 142 - Increased Risk of Developing Myeloid Neoplasms, Including Myelodysplastic Syndrome, in Well-Differentiated Thyroid Cancers Treated with Radioactive Iodine
19. MUTATIONAL SIGNATURE AND CLONAL ARCHITECTURE OF LOW RISK MYELODYSPLASTIC SYNDROMES
20. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine
21. A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia
22. Erratum: Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter
23. Increased Risk of Developing Myeloid Neoplasms, Including Myelodysplastic Syndrome, in Well-Differentiated Thyroid Cancers Treated with Radioactive Iodine
24. Adding Molecular Data to Prognostic Models can Improve their Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS)
25. Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
26. The complexity of interpreting genomic data in patients with acute myeloid leukemia
27. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms
28. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
29. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes
30. 20 SOMATIC MUTATIONAL MODEL TO PREDICT RESPONSE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES
31. 310 RISK OF BONE MARROW FAILURE CONDITIONS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES
32. 79 RISK OF MYELODYSPLASTIC SYNDROMES IN WELL-DIFFERENTIATED THYROID CANCERS TREATED WITH RADIOACTIVE IODINE
33. 53 - Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
34. 50 - Adding Molecular Data to Prognostic Models can Improve their Predictive Power in Treated Patients with Myelodysplastic Syndromes (MDS)
35. 10 - Mutational Signature and Clonal Architecture of Low Risk Myelodysplastic Syndromes with Del(5Q)
36. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine
37. A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia
38. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms
39. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
40. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells
41. Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α
42. 299 SOCS1 methylation and azacitidine response in high risk myelodysplasia (MDS) and secondary acute myeloid leukemia (AML)
43. Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML).
44. Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC).
45. Erratum: Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer
46. p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage.
47. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer.
48. DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
49. Acute lymphoblastic leukemia: Clinical practice guidelines in oncology
50. Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.